Impact of HCV genotype on treatment regimens and drug resistance: a snapshot in time by Cuypers, Lize et al.
R E V I E W
Impact of HCV genotype on treatment regimens
and drug resistance: a snapshot in time
Q1 Lize Cuypers1*, Francesca Ceccherini-Silberstein2, Kristel Van Laethem1,
Guangdi Li1,3, Anne-Mieke Vandamme1,4 and Jürgen Kurt Rockstroh5
1Department of Microbiology and Immunology, Rega Institute for Medical Research, Clinical and
Epidemiological Virology, KU Leuven—University of Leuven, Leuven, Belgium
2Department of Experimental Medicine and Surgery, University of Rome Tor Vergata, Rome, Italy
3Department of Metabolism and Endocrinology, Metabolic Syndrome Research Center, Key Laboratory of
Diabetes Immunology, Ministry of Education, National Clinical Research Center for Metabolic Diseases, The
Second Xiangya Hospital, Central South University, Changsha, Hunan, China
4Center for Global Health and Tropical Medicine, Microbiology Unit, Institute for Hygiene and Tropical
Medicine, University Nova de Lisboa, Lisbon, Portugal
5Department of Medicine I, University Hospital Bonn, Bonn, Germany
SUMMARY
The introduction of highly potent direct-acting antivirals (DAAs) has revolutionized hepatitis C virus treatment. Nev-
ertheless, viral eradication worldwide remains a challenge also in the era of DAA treatment, because of the high asso-
ciated costs, high numbers of undiagnosed patients, high re-infection rates in some risk groups and suboptimal drug
efﬁcacies associated with host and viral factors as well as advanced stages of liver disease. A correct determination
of the HCV genotype allows administration of the most appropriate antiviral regimen. Additionally, HCV genetic
sequencing improves our understanding of resistance-associated variants, either naturally occurring before treatment,
acquired by transmission at HCV infection, or emerging after virological failure. Because treatment response rates, and
the prevalence and development of drug resistance variants differ for each DAA regimen and HCV genotype, this re-
view summarizes treatment opportunities per HCV genotype, and focuses on viral genetic sequencing to guide clinical
decision making. Although approval of the ﬁrst pan-genotypic DAA-only regimen is expected soon, HCV genetic se-
quencing will remain important because when DAA therapies fail, genotyping and resistance testing to select a new
active DAA combination will be essential. Copyright © 2016 John Wiley & Sons, Ltd.
Received: 16 March 2016; Revised: 11 June 2016; Accepted: 15 June 2016
BACKGROUND
Since the discovery of HCV [1], a preventive vac-
cine remains elusive, resulting each year into two
million new infections [2]. Because of its high ge-
netic variability, HCV manifests into seven geno-
types (GTs) and more than 50 subtypes [3], all
varying in geographical distribution, prevalence,
level of genetic diversity [4] and pre-existing DAA
resistance variants [5]. HCV GTs 1–3 circulate
worldwide, whereas GTs 4–6 are more restricted
to speciﬁc geographical areas (Figure F11). Globally,
GT1 accounts for almost half of all infections,
followed by the second most prevalent GT3 [6,7].
Based on the presence of HCV RNA [8],
approximately 80 (64–103) million people are
chronically infected with HCV [9]. HCV infected
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3DAA, triple DAA combination; ASV, asunaprevir; BOC, boceprevir;
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daclatasvir; DSV, dasabuvir; EBR, elbasvir; GT, genotype; GZR,
grazoprevir; HCC, hepatocellular carcinoma; IU, international units;
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patients are at risk to develop cirrhosis, end-stage
liver diseases and hepatocellular carcinoma
(HCC), with increasing numbers of mortality cases
reported in the last years. They are also the source
of continuing new infections. The HCV healthcare
burden, for the four to ﬁve million people co-
infected with HIV [10], is even higher because of a
higher prevalence of cirrhosis and HCC cases
[11,12]. The primary goal of HCV treatment is
sustained virological response (SVR), which is de-
ﬁned as an undetectable viral load 12 or 24weeks
after end of therapy. The secondary goal is preven-
tion of related liver complications, because viral
cure is associated with a lower risk for morbidity
and mortality, albeit to a lesser extent for
HIV/HCV co-infected patients [13–16]. However,
when therapy is initiated at a late stage and evolu-
tion to cirrhosis has already started, risk reduction
for morbidity and mortality is smaller but not ab-
sent, warranting continued HCC screening, even
after achieving SVR. All HCV mono- and co-
infected patients, treatment-naïve or -experienced
with chronic liver disease, willing to be treated
and without contraindications for treatment,
should be considered for therapy [17,18]. However,
certain patient groups should be prioritized and
regimens should be chosen with consideration of
host and viral factors.
Genotype-dependent treatment regimens
Before 2011, the only therapeutic option for HCV
infected patients was the combination of pegylated
interferon-α (pegIFN-α) and ribavirin (RBV) for
24–72weeks, however, associated with severe
adverse effects and varying effectiveness in differ-
ent HCV GTs (Figure F22). HCV GTs 1, 4, 5 and 6
showed SVR rates of ~50% in HCV mono-infected
patients and lower than 30% in HIV/HCV
co-infected patients [19], whereas higher SVR rates
were achieved for GTs 2 and 3. The HCV genotype
was therefore the most important baseline predic-
tor for response to antiviral therapy based on
pegIFN-α and RBV [20]. The advent of DAAs,
which speciﬁcally target the NS3/4A protease,
NS5A or NS5B polymerase [21], dramatically im-
proved the efﬁcacy of treatment strategies. Adding
ﬁrst generation NS3/4A protease inhibitors, such
as boceprevir (BOC) and telaprevir (TVR), to
pegIFN-α and RBV, increased SVR rates to more
than 70% in HCV GT1-infected patients [22].
However, these drugs were also associated with
limited pan-genotypic activity, severe side effects
and rapid emergence of drug resistance variants
[23]. More efﬁcacious viral suppression is currently
achieved by oral DAA-only combination therapy
with SVR rates higher than 90%, broader antiviral
activity, less viral escape variants and less adverse
Figure 1. World map of the predominant HCV genotype in each country. This choropleth map shows the most prevalent HCV genotype
per country, using the Robinson’s projection, with the visualization software QGIS version 2.8.5-Wien (http://qgis.org/en/site/). HCV ge-
notypes 1a and 1b are shown in the same color as HCV genotype 1 and for countries where prevalence of HCV1a and HCV1b are distin-
guished, hatching is used to indicate the prevalent subtype. In light grey, countries are visualized for which no data or conﬂicting data
were reported. Data to construct this map were obtained through extensive literature search [6,7], with the respective references indicated
in the Supporting Information
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events [22–30] (Figure 2). TableT1 1 summarizes
genotype-dependent SVR rates for the main clinical
trials, approved regimens or experimental inhibi-
tors in late clinical stages. These clinical trials are
focusing on treatment-naïve and -experienced
patients, while some also include HIV/HCV
co-infected and cirrhotic populations. TableT2 2 lists
all currently approved drugs for the three different
DAA classes.
HCV genotype 1
Despite high SVR rates, interferon-based regimens
as mentioned in Table 1 (section A) are no longer
recommended for HCV GT1 infected patients
[17,18], given the good performance of ﬁve
approved IFN-free regimens and one combination
licensed only in Japan. The regimen SOF+VEL is
expected to be approved soon.
SOF+SMV
Results of four trials (1–4) (Table 1 section B) and
three real-life cohorts (5) for the regimen of
NS3/4A protease inhibitor simeprevir (SMV) and
NS5B polymerase inhibitor sofosbuvir (SOF), with
or without RBV, have been reported. (1) This regi-
men resulted in SVR12 rates of 93% for therapy-
naïve and –experienced patients in the COSMOS
study [31]. (2) During the OPTIMIST-1 trial lower
SVR rates were demonstrated when treatment
duration was shortened from 12 to 8weeks in
non-cirrhotic patients, either therapy-naïve (85%
vs 97%) or -experienced (77% vs 95%) [32].
Figure 2. Sustained virological response (SVR) rates of HCV antiviral treatment through time. In the last years, HCV antiviral treatment
has evolved from an IFN-based treatment to several IFN-free treatment options, characterized by differences in antiviral activity towards
the six main HCV genotypes. SVR rates are deﬁned as an undetectable viral load 12 or 24 weeks after stop of treatment. These SVR results
are visualized through time (for details see Table 1), for the different regimens approved, split up for the different genotypes (GTs). As
speciﬁed in the legend, the different categories of SVR rates are colored from red to green and with a white box indicating that this reg-
imen was not approved for this particular HCV genotype or no in vivo data is available. All regimens are indicated by their abbreviations,
more particularly boceprevir (BOC), daclatasvir (DCV), elbasvir (EBR), grazoprevir (GZR), ledipasvir (LDV), paritaprevir boosted with ri-
tonavir, ombitasvir and dasabuvir (3DAA), ribavirin (RBV), simeprevir (SMV), sofosbuvir (SOF), telaprevir (TVR) and velpatasvir (VEL)
3HCV genotyping for treatment and drug resistance
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Although similar SVR rates were observed for pa-
tients with a baseline HCV RNA level below 4 mil-
lion IU/ml, shortening of therapy duration based
on baseline viral load is not yet recommended. (3)
For cirrhotic patients, therapy duration should be
extended to 24weeks, with or without RBV, to de-
crease the risk of relapse [33]. (4) Higher SVR rates
were observed for SMV+SOF compared to
SOF+pegIFN-α+RBV in HCV GT1a cirrhotic pa-
tients [34]. (5) Large-scale real-life cohorts reported
similar high SVR rates [35,36], although lower for
cirrhotic HCV mono-infections [37].
SOF+DCV
High SVR rates were reported for SOF and NS5A
inhibitor daclatasvir (DCV) in three clinical trials
(1–3) (Table 1 section C), and in compassionate use
programs (4). (1) Therapy-naïve or -experienced pa-
tients were randomly assigned to treatment arms
containing SOF+DCV, resulting into SVR rates of
98% for GT1 [38]. (2) In the ALLY-2 trial, including
HIV/HCV GT1 co-infected patients, SVR rates of
96% and 76%were reported for treatment-naïve pa-
tients, treated for 12 or 8weeks, similar to the results
of therapy-experienced patients treated for
12weeks [39]. (3) SVR rates of ALLY-1 resulted into
the recommendation to extend treatment duration
to 24weeks for all GT1a infected patients, with or
without RBV [40]. Despite limited evidence, the
same approach was applied for GT1b. (4) Large co-
horts in compassionate use programs suggest that
cirrhotic patients may beneﬁt from a longer therapy
of 24weeks [41–43]. Nevertheless, no clinical beneﬁt
in the context of disease complications and mortal-
ity was found for patients with severe recurrent
HCV after liver transplantation [44].
SOF+LDV
The ﬁxed-dose combination of SOF and NS5A in-
hibitor ledipasvir (LDV) was studied during eight
clinical trials (Table 1 section D). (1)–(2)–(3) In the
three ﬁrst ION trials, high SVR rates were achieved,
irrespective of treatment duration or addition of
RBV, including (non-)cirrhotic therapy-naïve and -
experienced patients [45–47]. SOF+LDV for
8weeks may be considered in treatment-naïve,
non-cirrhotic patients with a baseline viral load
(VL) below 6 million IU/ml, as determined by the
Roche Cobas TaqmanHCVassay [48], although this
cut-off remains debaTable [49]. (4) All HIV/HCVTa
b
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co-infected patients except for one, cured their
infection during the ERADICATE trial [50]. (5) Sim-
ilar SVR rates were obtained for HIV/HCV co-
infected patients (ION-4), regardless of cirrhotic
status or prior treatment [51]. Nevertheless, inclu-
sion criteria of cirrhotic patients in trials have been
reported to be discordant with real-life cohorts
[52]. (6) For this difﬁcult-to-treat cirrhotic group,
an increase in SVR for treatment-experienced pa-
tients was observed when RBV was added or ther-
apy was extended to 24weeks [53]. (7) In the
SIRIUS study, prior PI-experienced cirrhotic pa-
tients yielded SVR12 rates of 96%, when treated
for 24weeks or 12weeks with RBV [54]. (8) Patients
with advanced liver disease, were treated for 12 or
24weeks in the SOLAR studies, showing high SVR
rates [55,56].
PTV/r+OBV+DSV+RBV
The triple DAA regimen of NS3/4A protease inhib-
itor paritaprevir (PTV) boosted with ritonavir (/r),
NS5A inhibitor ombitasvir (OBV) and NS5B poly-
merase inhibitor dasabuvir (DSV), was evaluated
in eight clinical trials (1–8) (Table 1 section E), and
high SVR rates were conﬁrmed in the TRIO net-
work and in a German study [57,58]. (1–2) In the
SAPPHIRE trials, this regimen was efﬁcacious in
both therapy-naïve and -experienced patients, al-
though in cirrhotic GT1a infected patients a longer
treatment period of 24weeks instead of 12weeks
was required [59,60]. (3–5) All GT1a and GT1b pre-
viously untreated patients achieved high SVR rates
during the PEARL studies [61,62]. Rates of virolog-
ical failure were higher without RBV than with RBV
among HCV GT1a but not among GT1b [62]. (6)
HIV/HCV co-infected patients in TURQUOISE-I,
including (non-)cirrhotic therapy-naïve and -
experienced patients, obtained SVR rates of 91–
94%, regardless of treatment duration or time of
ﬁrst virological response [63]. (7) Additionally, high
SVR rates were reported for cirrhotic patients [64].
(8) Recently, GT1b-infected patients with compen-
sated cirrhosis and prior therapy-failure, were able
to achieve 100% SVR using this 12-week regimen
without RBV, suggesting that RBVand longer treat-
ment durations are only beneﬁcial for GT1a infected
patients [65].
ASV+DCV
For GT1b therapy-experienced patients, treated
with NS3/4A PI asunaprevir (ASV) and DCV
(Table 1 section F), SVR rates of 77% and 95% were
achieved, the latter when combined with pegIFN-
α+RBV [66,67]. Overall, more viral breakthroughs
were observed for GT1a infected patients, even
when treated for 24weeks [68]. For HIV/HCV co-
infected and cirrhotic patients, promising results
were reported [69,70].
GZR+EBR
The ﬁxed-dose combination of NS3/4A PI
grazoprevir (GZR) and NS5A inhibitor elbasvir
(EBR), which was recently approved in the United
States, showed promising results in seven trials
(Table 1 section G). (1) Respectively 92% and 99%
of the (non-)cirrhotic GT1a and GT1b treatment-
naïve patients, were virologically cured in the
C-EDGE trial [27]. (2) For treatment-experienced
patients, treated either for 12 or 16weeks, SVR rates
of 92–94% and 92–97% respectively were achieved,
Table 2. Summary of direct-acting antivirals approved for clinical use. For all three drug
classes, NS3/4A protease inhibitors, NS5A inhibitors and NS5B polymerase inhibitors, the
names of the drugs currently approved for clinical use or described in this paper, and
their respective abbreviation, are listed
Approved direct-acting antivirals
NS3/4A protease inhibitors NS5A inhibitors NS5B polymerase inhibitors
Telaprevir (TVR) Daclatasvir (DCV) Sofosbuvir (SOF)
Boceprevir (BOC) Ledipasvir (LDV) Dasabuvir (DSV)
Simeprevir (SMV) Ombitasvir (OBV)
Asunaprevir (ASV) Elbasvir (EBR)
Paritaprevir (PTV) Velpatasvir (VEL)
Grazoprevir (GZR)
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depending on the addition of RBV [71]. (3) For pa-
tients who previously failed a PI-based therapy,
high SVR rates were achieved when RBV was
added [72]. (4) In prior untreated HCV mono- and
co-infected patients without cirrhosis, SVR12 rates
of 87–98% were reported, either without or with
RBV [73]. (5) A large trial enrolling HIV-1
therapy-naïve patients co-infected with HCV, with
or without cirrhosis, reported overall SVR12 rates
of 96% [74]. (6) Both treatment-naïve and -
experienced patients with chronic kidney disease
stages 4–5 were studied in the C-SURFER trial,
resulting into overall SVR of 99% [75]. (7) An inte-
grated analysis of compensated cirrhotic patients
showed that for therapy-experienced patients in-
fected with GT1b, a 12-week regimen is sufﬁcient
compared to GT1a infected, which beneﬁt from an
extended treatment duration to 16 or 18weeks,
and the addition of RBV [76].
Pipeline: SOF+VEL
The ﬁrst 12-week ﬁx-dose combination of SOF and
NS5A inhibitor velpatasvir (VEL) (Table 1 section
H) was studied in ASTRAL-1, in prior untreated
and treated patients, including those with cirrhosis,
demonstrating SVR rates of 99% [77]. Studying the
regimen more in depth for patients with decom-
pensated cirrhosis (ASTRAL-4) showed SVRs of
83%, 94% and 86%, respectively for 12weeks,
12weeks+RBV and 24weeks [78]. Pooled analysis
resulted into therapy efﬁcacy proven for all GTs
[79]. Concerning HIV/HCV co-infected patients,
SVR rates of 95% were achieved for all HCV geno-
types, irrespective of cirrhosis status or treatment
history [80].
Pipeline: ABT-493+ABT-530
High efﬁcacy was demonstrated for the combina-
tion of next-generation DAAs, NS3/4A protease in-
hibitor ABT-493 and NS5A inhibitor ABT-530, for
all HCV genotypes, irrespective of cirrhosis status
[81,82]. Nevertheless, larger trials are needed to
conﬁrm the very promising initial results for cir-
rhotic patients. A shorter treatment duration of
8weeks resulted into equal high SVR12 rates for
non-cirrhotic patients with HCV GT1 or 2 infec-
tions (97–98%) [83]. For patients who previously
failed a DAA-containing regimen, the new combi-
nation showed high efﬁcacy, irrespective of RBV,
in the MAGELLAN-I study [84].
HCV genotype 2
SOF+RBV has become the gold standard to treat
HCV GT2 infected patients. Other options to treat
these patients are SOF+RBV+pegIFN and
SOF+DCV. Soon the dual DAA regimen
SOF+VEL will be added to this list.
SOF+RBV
This regimen was tested during seven clinical trials
(1–7) (Table 1 section I), and one real-life cohort (8).
(1) Previously untreated patients were randomly
assigned to receive SOF+RBV for 12weeks, or
pegIFN-α2a+RBV for 24weeks, resulting into an
SVR of 95% for the ﬁrst group (FISSION) [25]. (2)
Patients for whom a therapy consisting of IFN is
not an option or who previously did not respond
to IFN (FUSION), achieved SVR rates of 86% and
94%, when treated for 12 or 16weeks [85]. (3) Dur-
ing the POSITRON trial, 93% of the patients consid-
ered as IFN-intolerant, virologically cured their
viruses [85]. (4) The VALENCE study obtained
high SVR rates, irrespective of previous treatment
or disease progression [86]. (5) In the BOSON
study, SVR12 rates of 87%, 100% and 94% were
achieved for hard-to-treat patients, respectively
for SOF+RBV 16weeks or 24weeks and
SOF+RBV+pegIFN 12weeks [87]. (6–7) In the
PHOTON studies, HIV/HCV co-infected patients
achieved high SVR rates irrespective of cirrhotic
status [88,89]. (8) Real-world data conﬁrmed the
lower SVR rates for cirrhotic patients [36,90],
whereas large trials are still needed to determine
whether 16weeks is the correct treatment duration
for these patients.
SOF+pegIFN-α+RBV
Adding pegIFN-α to SOF+RBV (Table 1 section A)
was studied in the LONESTAR-2 trial, resulting
into SVR rates of 96% [91], similar to the IFN-free
variant which achieved overall SVR rates of 95%
(FISSION) [25].
SOF+DCV
SVR rates of 92% were reported for the regimen
SOF+DCV (Table 1 section C), independent of
therapy duration (AI444-040 and ALLY-1)
[38,40,92]. Based on data of other GTs, 12weeks of
therapy is probably sufﬁcient. Because of this lower
success rate (<95%) and the high cost associated to
10 L. Cuypers et al.
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the combination, this regimen should only be used
when other options are not available.
Pipeline: SOF+VEL
The regimen SOF+VEL is a forthcoming combina-
tion for GT2 (Table 1 section H), because high SVR
rates were observed, even for cirrhotic patients
(ASTRAL-1) [77,78]. Its efﬁcacy was compared to
SOF+RBV in the ASTRAL-2 and -3 studies, reveal-
ing the superiority of this new regimen (SVR 99%
vs 94%) [93,94]. Similar SVR rates were docu-
mented in HIV/HCV co-infected patients [80].
Pipeline: ABT-493+ABT-530
High SVR12 rates were achieved for cirrhotic and
non-cirrhotic patients treated with the combination
ABT-493+ABT-530 [81,82], even when treated for a
shorter period of 8weeks [83].
HCV genotype 3
Standard treatment schemes have evolved from
IFN-based to IFN-free combinations. While GT1
used to be the most difﬁcult-to-treat HCV geno-
type, this has now shifted to GT3, being the main
genotype where currently IFN-containing regimens
are still an option. GT3 is also associated with a
higher prevalence of liver steatosis [95]. The regi-
mens SOF+RBV, SOF+DCV, or
SOF+pegIFN+RBV are used.
SOF+RBV
SVR rates for GT3 infected patients (Table 1 section
I) (1) were lower (56%) compared to those infected
with GT2 (95%), when treated for 12weeks (FIS-
SION) [25]. Patients for whom IFN therapy was
not an option, were included in the FUSION and
POSITRON trials, (3) resulting in SVR12 rates of
61%. (2) When treatment duration was extended
to 16weeks among prior treated patients, SVR in-
creased dramatically (62% vs 30%) [85]. (4) Extend-
ing duration to 24weeks resulted in even higher
SVR rates of 85–90%, both for prior treated and un-
treated patients, although lower efﬁcacy was re-
ported for cirrhotic patients, especially in
treatment-experienced patients (VALENCE) [86].
Therefore, SOF+RBV for 24weeks is only recom-
mended in non-cirrhotic patients, while it is consid-
ered suboptimal in patients with cirrhosis.
SOF+DCV
High SVR rates in therapy-naïve patients (AI444-
040) [38] and -experienced patients (ALLY-3 study)
[26] were conﬁrmed during a multicenter compas-
sionate use program, suggesting that cirrhotic
GT3 infected patients may beneﬁt from a treatment
of 24weeks [96] (Table 1 section C). Nevertheless,
treatment of GT3 infected patients with decompen-
sated cirrhosis for 12weeks with SOF+DCV+RBV
resulted into SVR rates of over 70% [43]. Recently,
SVR4 rates of 88% and 96% were obtained for the
12- and 16-week arms in the ALLY-3+ study, in-
cluding patients with advanced ﬁbrosis and cirrho-
sis; however, only when ribavirin was added [97].
SOF+LDV
To date, SOF+LDV is not recommended to treat
GT3 infections [17,18], because all data from trials
and early access programs did not show high
enough SVR rates, and little antiviral activity was
observed in vitro for LDV [98]. Lower SVR rates
were observed for SOF+LDV compared to
SOF+DCV in the ELECTRON-2 trial [43], with for
the regimen SOF+LDV also lower rates were re-
ported for cirrhotic versus non-cirrhotic patients
(73% vs 89%) [99].
SOF+pegIFN-α+RBV
This regimen remains a good option for HCV GT3
(Table 1 section A), because high efﬁcacy was re-
ported for treatment-naïve and -experienced pa-
tients, proving superiority compared to
SOF+RBV for 12 or 24weeks (NCT01188772 and
BOSON) [90,91,100]. The LONESTAR-2 study ob-
tained SVR rates of 83% in prior treated patients,
suggesting its use in difﬁcult-to-treat patients [91].
Pipeline: SOF+VEL
This regimen will soon enter the antiviral drug
market (Table 1 section H), because higher SVR
was reported compared to SOF+RBV, in the
ASTRAL-2 and -3 trials [93,101].
Pipeline: ABT-493+ABT-530
HCV GT3 infected patients were separately studied
for ABT-493+ABT-530 after obtaining high SVR
rates in general [81,82]. So far, no virological failure
has been observed with this combination, of which
the ﬁrst study included only non-cirrhotic patients
and a second focused speciﬁcally on cirrhotic
11HCV genotyping for treatment and drug resistance
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patients [102,103]. Non-inferiority to SOF+DCV
has been shown in the ENDURANCE-3 trial [104]
and results of cirrhotic treatment-experienced
HCV GT3 patients are expected soon.
HCV genotype 4
HCV GT4 infections are increasing in prevalence
worldwide, represented by a high variety of sub-
types. For these patients, SOF+pegIFN+RBV
(NEUTRINO and NCT01565889) [25,105] and four
IFN-free regimens were approved.
SOF+RBV
This regimen was evaluated in two Egyptian trials,
resulting in SVR rates of 68–77% or 90–93%, either
for a 12- or 24-week treatment [106,107] (Table 1
section I). In the PHOTON-II study, a small group
of HIV/HCV co-infected patients were treated for
24weeks, resulting into SVR rates of 84% [89].
PTV/r+OBV+/RBV
Table 1 section E describes a triple (adding DSV in
GT1) or dual (GT4) DAA regimen. Because DSV
shows exclusive antiviral activity towards GT1
[28], in the PEARL-I study, non-cirrhotic GT4 in-
fected patients were treated with a dual DAA regi-
men, achieving high SVR rates, independent of
prior therapy-experience [108]. In the AGATE-I
and -II studies, this combination showed high
SVR rates in cirrhotic patients after therapy for 12,
16 and 24weeks [109,110].
SOF+LDV
SVR rates of 95% were reported for therapy-naïve
patients, supporting the role of SOF+LDV in GT4
infected patients (NCT01826981 and SYNERGY)
[111,112] (Table 1 section D). Replacing LDV with
DCV was tested in a multicenter compassionate
use program [42], with SVR rates of 100%.
GZR+EBR and in pipeline: SOF+VEL and
ABT-493+ABT-530
For GZR+EBR (Table 1 section G), overall SVR
rates of 95% were reported in treatment-naïve pa-
tients, either mono- or co-infected patients (C-
EDGE) [27,74]. Pooled analysis showed improved
SVR rates when RBV was added and duration
was extended to 16weeks in case of prior on-
treatment virological failure [113]. Soon, SOF+VEL
will be available, reported to have 99% SVR rates
[77] (Table 1 section H). SVR12 rates of 100% have
been reported for ABT-493+ABT-530 in HCV GT4
[81,82,114].
HCV genotype 5–6
Currently, only two regimens have been approved
to treat patients infected with HCV GTs 5 and 6, be-
cause clinical studies are limited (Table 1 sections C
and D). Treatment with SOF+LDV for 12weeks in
treatment-naïve and -experienced patients resulted
in SVR rates of 95–96% (GT5: NCT01826981 [111]
and GT6: preliminary data of the ELECTRON-2
study [99]), however slightly lower in cirrhotic pa-
tients. Patients can also be treated with SOF+DCV,
however only based on extrapolation of results ob-
tained in other GTs. In the NEUTRINO trial,
SOF+pegIFN-α+RBV resulted into 100% SVR for
GT5 [25] (Table 1 section A). Soon the regimens
GZR+EBR [27] and SOF+VEL [77,78] will be
available as well (Table 1 section G and H), with
SVR rates in the range of 95–99%. SVR12 rates of
100% were also reported for HCV GTs 5-6, using
ABT-493+ABT-530 [114].
HCV genotyping assays as a prognostic tool:
selection of treatment
In the DAA era, the correct determination of the
HCV genotype remains important to guide the se-
lection of the most appropriate treatment scheme
for each patient [17,18], as even the DAAs do not
harbor equal antiviral activity across all GTs
[115,116] (Table 1). Commercial assays are available
for determining HCV genotype and subtype, all
targeting the highly conserved and best-
characterized 5′ untranslated region. However, be-
cause this region has been shown inappropriate to
discriminate certain HCV strains [117], the two
most used diagnostic assays, Abbott RealTime
HCV Genotype II and INNO-LiPA-HCV-2.0, also
target the NS5B or the core gene, providing addi-
tional information to distinguish GT1a and 1b
[118]. Nevertheless, they can still assign strains as
GT1 without subtype, as ‘undetermined’ or ‘mixed’
[118], making it necessary to use in-house sequenc-
ing to correctly assign the HCV GT. Reports about
the concordance between subtyping results from
commercial assays and sequence-based genotyp-
ing, focus mainly on GT1 unresolved infections
and are biased because in-house methods are often
genotype- or subtype speciﬁc and target different
12 L. Cuypers et al.
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regions of the HCV genome which may potentially
differ if recombination has happened. However, in
contrast to HIV which has a strong tendency to un-
dergo intra- and inter-subtype recombination, this
phenomenon has only sporadically been described
for HCV. Although the Abbott assay was able to re-
solve 90% of the GTs, additional testing using
core/E1, NS3, NS5A or NS5B assays, was required
in 9–10% of the cases to fully resolve the GT [119–
121]. Genotyping through sequencing can gather
additional information about the presence of drug
resistance variants; moreover, the HCV GT also im-
pacts prevalence and development of resistance-
associated variants (RAVs).
Only few cases have been reported concerning
mixed HCV GT infections, mainly in persons
who inject drugs (PWID) and patients on
hemodialysis or multiple transfusions [122,123].
In these infections, one of the GTs prevails,
because they differ in replication efﬁcacy or viral
interference. As commercial assays are not al-
ways able to identify the minor genotype(s) that
exist(s) aside the dominant genotype [124], their
impact on SVR rates with DAAs should be
considered [125].
Known RAVs to DAAs
Because of the high error prone HCV RNA poly-
merase coupled with a 100-fold higher virion pro-
duction than HIV [126], HCV replicates as a
population of closely related viral variants within
a patient. It has been predicted that each nucleotide
within the HCV genome theoretically can be
substituted every day, with most RAVs or nowa-
days called resistance-associated substitutions
(RASs) produced naturally during the replication
cycle [127,128]. The frequency of these RAVs de-
pends on multiple factors, such as replication ﬁt-
ness, ﬁtness cost and genetic barrier to resistance
[129]. Theoretically it is possible to detect a single
RAV against any of the three DAA classes as mi-
nority variants in all patients prior to treatment,
while virological failure of combination therapies
would require multiple RAVs on multiple drug tar-
gets [130]. Combinations of multiple RAVs to the
recommended IFN-free regimens are however
rarely detected in DAA-naïve patients [131].
Resistance to NS3/4A protease inhibitors
Protease inhibitors (PIs) interact with the enzyme
substrate binding site and prevent cleavage of the
HCV polyprotein into several non-structural pro-
teins. Virological failure with ﬁrst generation PIs
is often associated with the emergence of RAVs
[132], more speciﬁcally the most prevalent
V36A/M, T54A/S, V55A, Q80R/K, R155K/T,
A156S/T/V, I/V170A and D168A/E/K/T/V/Y
[23] (Figure F33A), of which only A156V/T confers
high level of resistance [133]. Drug resistance
strains were found in more than 80% of the patients
who failed triple therapy with TVR or BOC. Cross-
resistance between the ﬁrst- and second-wave PIs
was observed for variant R155K and for amino acid
substitutions at residue D168, with the latter
mainly known to confer resistance to second-wave
PIs [134]. Prevalence of RAVs after therapy failure
varies according to genotype [5], for example, vari-
ant R155K is mainly found in GT1a, while for GT1b
A156T/V is more frequent, because two nucleotide
substitutions are required for GT1b to develop
R155K. GZR retains potent antiviral activity even
in the presence of the key RAVs mentioned above,
although viruses with substitutions at NS3 position
A156 and D168 display some reduced susceptibil-
ity [135,136].
Resistance to NS5A inhibitors
The exact function of NS5A is still obscure. It
regulates viral replication, participates in assem-
bly and release of HCV particles and displays
several interactions with host proteins. NS5A in-
hibitors interact with domain I of the NS5A di-
mer, but the inhibitory mechanism remains
unclear [137]. Nevertheless, it has been recently
suggested that the binding of inhibitors to a
drug-resistant NS5A protein causes conforma-
tional changes [138,139]. The most important
RAVs to NS5A inhibitors are M/L28T/V,
Q/L30E/H/R/S, L31M/V, H58D and Y93C/H/
N [98,127] (Figure 3B). DCV and LDV display
similar potencies in HCV GT1a and GT1b wild-
type replicons during in vitro assays, although
DCV proved to be superior against resistant vari-
ant Y93H [98], which has a natural prevalence of
>10% and displays high level resistance to both
LDV and DCV in GT1b replicon cells [140]. Also
for HCV GTs 2–4, DCV has signiﬁcantly higher
potency in vitro compared to LDV [98], with the
highest fold resistance values for variant F28S in
GT2, Y93H in GT3, and RAVs on NS5A positions
30 and 93 for GT4 [140–142]. Variants conferring
13HCV genotyping for treatment and drug resistance
Copyright © 2016 John Wiley & Sons, Ltd. Rev. Med. Virol.
DOI: 10.1002/rmv
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
resistance towards EBR were studied for HCV
GT1a, GT1b and GT3 replicon cells [143]. No con-
sistent pattern of RAVs was observed for ﬁve re-
lapsers treated with a therapy containing VEL
[144], and no impact on treatment outcome was
reported for the presence of NS3 and NS5A RAVs
for ABT-493+ABT-530 in GT3 [103] or treatment-
experienced GT1 infected patients [83].
Figure 3. Drug resistant variants near the binding pocket of DAAs in HCV protein structures: (A) NS3/4A protease (NS3: pink, NS4A:
blue) in complex with simeprevir, (B) NS5A dimer in complex with daclatasvir and (C) NS5B polymerase in complex with sofosbuvir and
beclabuvir. NS3/4A protease inhibitors bind to the catalytic triad of the NS3 serine protease, which consists of the three amino acids H57,
D81 and S139. The mechanism of action of the NS5A inhibitors is not entirely understood, although it is known that they interact with the
NS5A domain I. With different mechanisms of action, nucleotide inhibitors (e.g. sofosbuvir) and non-nucleoside inhibitors (e.g.
beclabuvir) target the catalytic site and the allosteric site, respectively. Near the binding pocket, amino acid positions associated with drug
resistance towards the respective inhibitors are visualized in colored spheres (see legend). For the visualization, PDB data of HCV protein
structures were obtained from literature (NS5A [139]) and the Protein Data Bank (NS3/4A: 3KEE and 4B76, NS5B: 4NLD and 4WTG), using
visualization software: PyMOL V1.7 (http://www.pymol.org/). Interactive movies are available on http://www.virusface.com/HCV/
HCV_DrugResistance2016.html
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Resistance to NS5B polymerase inhibitors
The NS5B RNA polymerase of the membrane-
associated HCV replication complex is structurally
organized in a ‘right hand motif’ containing palm
and thumb domains [28]. Nucleos(t)ide inhibitors
mimic natural substrates that are incorporated into
the nascent RNA chain and result in chain termina-
tion, while non-nucleoside inhibitors (NNI) bind
outside the polymerase active site to allosteric
binding sites, resulting in no cross-resistance be-
tween the subclasses (Figure 3C). For the nucleo-
tide analog SOF, resistant replicon cells with a
single NS5B S282T variant were selected, confer-
ring decreased susceptibility to SOF [145]; how-
ever, this variant is rarely identiﬁed in clinical
cases [99,146]. In a pooled analysis of SOF, NS5B
substitutions L159F and V321A were selected
post-baseline in several infected subjects who did
not achieve SVR, with the highest proportion of
failures detected in HCV GT1a, GT2 and GT3 in-
fected patients [147]. Nevertheless, these RAVs
conferred only 1.2- to 1.6-fold reduced phenotypic
susceptibility to SOF in vitro [147]. NS5B variant
C316N/H/F was present at baseline in six GT1b in-
fected subjects who virologically failed and in one
GT1a relapsing patient [148]. The rare NS5B RAV
L320F was identiﬁed under therapy with SOF, pos-
sibly contributing to drug resistance [148]. For
NNI, commonly observed NS5B substitutions are
M414T and S556G [149], or A421V and P495L/S
[150].
Pre-existing drug resistant variants
In addition to RAVs emerging under DAA therapy
or acquired at infection by transmission from a
DAA-failing patient with resistance, they can also
pre-exist before treatment initiation as naturally oc-
curring variants within the viral population of an
infected patient, prior to drug selective pressure.
The NS3 RAV Q80K, associated with signiﬁ-
cantly lower SVR rates for treatment with
SMV+pegIFN-α+RBV [24], exists as a natural
polymorphism mainly in HCV GT1a [5]. In general,
NS3 RAVs were found in 19–31% of NS3 sequences
originating from all HCV genotypes [151,152], with
for the most prevalent variant Q80K a higher fre-
quency in GT1a (20–52%) compared to GT1b
(<1%) [5,134,153,154]. The presence of Q80K is es-
pecially problematic in cirrhotic patients, because
for GT1a infected patients treated with SMV+SOF,
lower SVR rates of 74% were observed in the pres-
ence of Q80K versus 92% in the absence of Q80K
[33]. Irrespective of Q80K, all non-cirrhotic patients
responded well [32]. Therefore, monitoring of
Q80K prior to therapy is recommended in all
HCV GT1a infected patients starting treatment
with SMV+pegIFN-α+RBV, while for therapy
with SMV+SOF, testing is needed only for cirrhotic
patients [17].
A large prevalence study of natural NS5A RAVs
across different countries showed substantial re-
gional differences [151,155], with a broad range of
6–25%. The most common NS5A RAVs were
L31M, Q54H and Y93H [146]. For the combination
ASV+DCV, in one study the NS5A variant Y93H
was observed in half of the failing patients prior
to treatment, all classiﬁed as HCV GT1b prior
null-responders to pegIFN-α+RBV. In a different
study, the UNITY-1 study, despite the higher rate
of NS5A RAVs at baseline detected in GT1b com-
pared to GT1a infected patients (16% vs 11%), all
GT1b infected patients achieved SVR in contrast
to only 74% for GT1a [156]. Higher SVR rates were
observed for patients lacking Y93H when treated
with SOF+DCV [157].
For SOF+LDV, natural RAVs were observed in a
higher proportion in HCV GT1b compared to GT1a
sequences [158]; however this was not associated
with lower SVR rates. Lower SVR rates for this reg-
imen were only reported for GT1a, in therapy-
experienced patients with RAVs conferring more
than 100-fold resistance [136,159]. Upon investigat-
ing the original baseline sequence in a study on pa-
tients failing 8 or 12weeks of SOF+LDV based
regimens, which were scheduled for retreatment
with the same regimen for 24weeks, a link was re-
vealed between the number of natural NS5A RAVs
and the observed SVR. Only 50% of the patients
that had two or more baseline resistance-related
variants cleared the virus, with the lowest SVR
rates observed with variant Y93H/N [160]. A re-
cent study showed that a longer duration of treat-
ment with SOF+LDV and addition of RBV can
reduce or even eliminate the impact of baseline
NS5A RAVs [161].
In prior null-responders to pegIFN-α and RBV,
the impact of natural NS5A variants on the efﬁcacy
of the GZR+EBR regimen in HCV GT1 was stud-
ied by next-generation sequencing (NGS). Espe-
cially HCV GT1a infected patients were affected,
because only 52% that harbored NS5A variants
15HCV genotyping for treatment and drug resistance
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with >5-fold shift to EBR were able to achieve SVR
[71,162]. For GT1a infected patients who initiate
treatment with GZR+EBR, it has recently become
recommended to monitor high fold-change NS5A
RAVs for EBR at baseline [17]. Naturally occurring
RAVs in NS5A seem to have little effect on
SOF+VEL or ABT-493+ABT-530, despite a high
prevalence of such variants, 97–100% achieved
SVR [77,102,103].
Based on eight SOF monotherapy and ﬁve
SOF+LDV trials, baseline sequences of 408 pa-
tients who virologically failed, were evaluated
using NGS [163]. NS5B variant L159F was de-
tected in 1% of the GT1 infected patients and
was only associated with increased virological
failure in patients treated for short durations with
SOF+RBV, but did not affect treatment outcome
with LDV+SOF [163]. A Russian study focused
on the comparison of SVR12 rates achieved in pa-
tients with and without variant L159F at baseline
and treated for 16weeks with SOF+RBV [164].
RAV L159F was mainly observed in GT1b (34%
prevalence) and was associated with decreased
SVR rates of 25% compared to 65% in patients
without this variant [164]. Other variants confer-
ring resistance towards NS5B polymerase inhibi-
tors did not have an impact on treatment
outcome, for example the highly prevalent RAV
C316N (48%) in HCV GT1b infected Japanese pa-
tients who initiated therapy with SOF+LDV
[146]. Also in the AVIATOR trial, evaluating the
regimen PTV/r+OBV+DSV, the most prevalent
NS5B RAV (>3%) S556G was not associated with
treatment response [130]. Nevertheless, in general
nucleoside inhibitor based regimens have a low
prevalence of natural RAVs [131].
Sequencing as prognostic tool: drug
resistance testing
Resistance testing is not routinely performed in
HCV clinical practice, in contrast to HIV where it
is recommended both prior to start of treatment
and during follow-up [165], in order to prevent
therapy failure. While in HIV patients, any resistant
variant remains archived in the proviral DNA, this
is not the case for HCV, with time, the virus turn-
over eliminates resistant variants that are often less
ﬁt. There is no need to compile historical resistance
information for the individual HCV patient to ﬁnd
the best treatment.
Declined persistence rates of RAVs post-
treatment were reported with differences for the
three DAA classes, indicating indeed that there is
a ﬁtness cost to the development of RAVs. While
for ﬁrst-generation PIs TVR and BOC, NS3 variants
were still detectable after one-year post-therapy
[23], a long-term follow-up of patients who failed
on BOC revealed that 73% of all NS3 RAVs
reverted to the wild-type within three years post-
therapy [166]. The one-year persistence rate of
NS3 RAVs for second wave or second generation
PIs was much lower (9%) [133]. NS5A and NS5B
RAVs persisted much longer, with respectively
96% and 57% of the variants still present 48weeks
after therapy with PTV/r+OBV+DSV [167]. For
NS5A inhibitors EBR and LDV, the majority of the
patients still carried detectable RAVs 93weeks after
treatment [168,169].
The only drugs for which a resistance test is re-
quired before therapy initiation are SMV and EBR
(Table T33). For combination regimens of
SMV+pegIFN-α+RBV, or SMV+SOF (in case of
cirrhosis) resistance testing should be considered
in HCV GT1a infected patients, because lower
SVR rates were reported in the presence of NS3 var-
iant Q80K, which has a high prevalence in this sub-
type [17,24,32]. Nevertheless, the regimen
SMV+pegIFN-α+RBV is no longer recommended
to use in GT1 infected patients. Recently, treatment
guidelines changed for HCV GT1a infected pa-
tients, because drug resistance testing is now also
recommended when treatment with GZR+EBR is
initiated [17]. When high fold-change NS5A RAVs
for EBR (M28A/G/T, Q30D/E/H/G/K/L/R,
L31F/M/V and Y93C/H/N/S) are detected at
baseline, treatment duration needs to be extended
from 12 to 16weeks and RBV needs to be added
to the regimen [17].
Nevertheless, also for other NS5A and NS5B
RAVs, monitoring RAVs before start of treatment
could be considered, even though the inﬂuence of
these variants on clinical outcome is not sufﬁ-
ciently known yet. For instance, NS5A variant
Y93H may be monitored in HCV GT1 before
treatment is started with ASV+DCV, because
the presence of this variant was associated with
therapy outcome in both GT1a and GT1b infected
patients [156]. For HCV GT1b infected patients
who want to start treatment with SOF, monitor-
ing of NS5B variant L159F could be considered
because decreased SVR rates were reported for
16 L. Cuypers et al.
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Table 3. Treatment indications [17,18] and genotyping or sequencing requirements for HCV
mono-infected or HCV/HIV co-infected patients with chronic HCV without or with
compensated cirrhosis, including treatment-naïve patients and patients who failed treatment
based on pegylated interferon-α (pegIFN-α) and ribavirin (RBV). Interferon-free and -based
regimens containing direct-acting antivirals asunaprevir (ASV), daclatasvir (DCV), dasabuvir
(DSV), elbasvir (EBR), grazoprevir (GZR), ledipasvir (LDV), ombitasvir (OBV), paritaprevir
(PTV) boosted with ritonavir (/r), simeprevir (SMV), sofosbuvir (SOF) and velpatasvir (VEL)
are summarized. Treatment schemes with and without cirrhosis (c) are listed, including
information about the weeks (w) of treatment and in case of cirrhotic patients the duration of
treatment with (+ RBV) and without ribavirin ( RBV). For the IFN-based regimen pegIFN-
α+RBV+SMV, after 12weeks, treatment is continued without SMV for an additional 12 of
24weeks (+12w or 24w). Genotyping refers to determining the genotype and subtype, it is
recommended before starting the indicated therapy, using assays designed for this purpose, or
using genetic sequencing. Sequencing refers to determining the nucleotide sequence of drug
target genes for resistance testing purposes [17,33,156,160,162]. The RAVs to the respective
treatments that are advised to be monitored are listed [5]. In the presence of these RAVs, a
different treatment may be chosen, either recommended (bold), or it could be considered to
adapt the regimen (plain text). Note that genetic sequencing can be used for both purposes
simultaneously
Regimen Genotype Genotyping Sequencing Treatment
Non-cirrhotic
Treatment Cirrhotic
SOF+RBV 2 Yes 12w 16–20w
3 24w Not recommended
SOF+LDV
(+ RBV)
1 Yes NS5A: Y93H 8–12w 12w (+ RBV) or
24w ( RBV)4+5+6 12w
12w (+ RBV) or
24w ( RBV)
OBV+PTV/r+
DSV (+ RBV)
1a Yes 12w (+ RBV) 24w (+ RBV)
1b 12w 12w (+ RBV)
SOF+SMV
(+ RBV)
1 Yes NS3: Q80K‡
(Only cirrhotic
GT1a patients)
12w 12w (+ RBV) or
24w ( RBV)
SOF+DCV
(+ RBV)
1+4+5+6 Yes NS5A: Y93H 12w 12w (+ RBV) or
24w ( RBV)2 12w
12w 12w
24w (+ RBV)3
OBV+PTV/r
(+ RBV)
4 Yes 12w (+ RBV) 24w (+ RBV)
GZR+EBR
(+ RBV)
1a Yes NS5A RAVs at
28, 30, 31, 93§
16w (+ RBV) 16w (+ RBV)
1b+4+5+6 12w 12w
ASV+DCV* 1 Yes NS5A: Y93H 24w 24w
SOF+VEL† All No 12w 12w
PegIFN-α+
RBV+SOF
3+4+5+6 Yes 12w 12w
*Treatment regimen only approved in Japan.
†In the pipeline, will soon become available.
‡NS3 variant Q80K is indicated in bold, because it is a RAV for which testing is recommended in GT1a: if Q80K is
detected, SMV+SOF should be avoided for cirrhotic patients [33].
§High fold-change NS5A RAVs for elbasvir which are recommended for testing in HCV GT1a infected patients [17] are
28A/G/T, 30D/E/H/G/K/L/R, 31F/M/V and 93C/H/N/S.
17HCV genotyping for treatment and drug resistance
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patients harboring this variant compared to pa-
tients lacking it [164].
Even when RAVs persist after failure of treat-
ment, the large number of therapies available and
the lack of cross-resistance among different classes
of DAAs imply that most HCV patients who failed
to achieve SVR with a speciﬁc DAA-based regimen
will be able to be retreated with other DAA thera-
pies [170], however with conﬂicting results when
RAVs are present [171,172]. However, HCV has a
larger genetic variability than HIV, and the preva-
lence of naturally occurring RAVs is much higher.
Therefore, viral sequencing can play a role as prog-
nostic tool to select the most appropriate second
line regimen for retreatment. Nowadays, experts
within the virology ﬁeld advise drug resistance
testing for all three target genes (NS3, NS5A and
NS5B), for all failing regimens, to guide the selec-
tion of a second line regimen (TableT4 4). This is not
only to detect drug resistance variants that
emerged under the failing therapy, but also to mon-
itor RAVs to other drug targets that are present as
natural occurring variants. It is too early to make
solid recommendations for retreatment based on
resistance testing, because studies assessing treat-
ment success in the presence or absence of particu-
lar resistance proﬁles are not available yet.
However, we do have information about resistance
proﬁles appearing in patients that failed a particu-
lar regimen. Therefore, therapeutic decisions can
be made based on HCV genotype, detected resis-
tance proﬁles, number of drugs used, use of RBV
and treatment duration.
Depending on the type of resistance detected and
the urgency of treatment, therapy could be post-
poned until more evidence is available to better
guide retreatment decisions. For example, in the
absence of cirrhosis, it is advised to either wait for
more active regimens or to administer at least two
fully active drugs, with a preferential use of one
drug with high genetic barrier to resistance,
and/or with extended treatment duration and ad-
dition of RBV (Table 4). A longer treatment of
GZR+EBR for 16weeks and addition of RBV was
recently recommended in patients who previously
failed the same regimen [17]. In patients failing
NS5A based therapies, retreatment regimens in-
cluding NS5A inhibitors are not advised, unless re-
sistance testing showed absence of NS5A RAVs or
presence of minor NS5A RAVs which do not neces-
sarily confer cross-resistance to the entire drug
class. When resistance information is absent, these
patients could be treated by shifting drug class to
a NS3 containing regimen, like SOF+SMV. Simi-
larly, patients failing NS3 based therapies can still
be treated with NS5A based regimens such as
SOF+DCV or SOF+LDV, in case resistance infor-
mation is absent or in the presence of high-fold re-
sistant NS3 RAVs. The most difﬁcult situation is
when designing a therapeutic approach for patients
who harbor RAVs to multiple DAA classes. These
patients currently have few retreatment options
with commercially available IFN-free combinations
and might be helped with multiple DAA combina-
tions targeting nearly all replication steps. This ap-
proach is currently under evaluation in some
clinical trials [173,174].
All therapy regimens with indications regarding
RAVs monitoring are listed in Tables 3 and 4. How-
ever, it is not clear yet what the best strategy is to
measure the presence of RAVs [175], Sanger popu-
lation sequencing which can detect variants down
to 20% of the population or NGS for which detec-
tion limits down to 1% have been reported [176].
Because of the higher intra-patient genetic variabil-
ity, minority variants are deemed more important
in HCVresistance development than for HIV. How-
ever, knowledge on the clinical relevance of detect-
ing variants at low levels is still scarce, the most
recent reports suggest 20% as a sufﬁcient threshold
to detect the most impactful RAVs [162]. Other
technical issues make HCV resistance testing quite
challenging, such as the design of genotype- and
subtype-speciﬁc PCR primers, error-rates and high
costs.
Sequencing as an epidemiological tool:
transmission investigation
Despite the high SVR rates associated with DAA
regimens, and the limited need for extensive drug
resistance testing compared to HIV, viral eradica-
tion of HCV on a global scale is still hampered, be-
cause of a vast majority of the HCV infected
population that is not aware of their status, the
high costs associated with these drugs, the un-
known impact of acquired drug resistance [177],
and the high re-infection rates in risk populations
(13% for PWID and 22% for HIV/HCV co-infected
patients) [178–180].
Therefore, genetic sequences are highly valuable,
not only for resistance testing but also for
18 L. Cuypers et al.
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Table 4. Treatment indications [17,18] and genotyping requirements for HCV mono-infected
or HCV/HIV co-infected patients with chronic HCV who failed to achieve an SVR on prior
antiviral therapy containing one or more direct-acting antivirals (DAA’s). Patients who
previously failed treatment regimens can be retreated with several treatment schemes,
including daclatasvir (DCV), dasabuvir (DSV), ledipasvir (LDV), ombitasvir (OBV),
paritaprevir (PTV) boosted with ritonavir (/r), pegylated interferon-α (pegIFN-α), ribavirin
(RBV), simeprevir (SMV) and sofosbuvir (SOF). New therapies are administered to HCV
infected patients for a different number of weeks (w) in non-cirrhotic and cirrhotic (c)
patients. For all failing regimens, drug resistance testing of all three genes (NS3, NS5A and
NS5B) is advised before retreatment. Depending on the type of resistance, if treatment is
not urgent, therapy should be postponed. In case of absence of cirrhosis, it is advised to
either wait for more active regimens or to administer at least two fully active drugs, with a
preferential use of one drug with high genetic barrier to resistance, and with extended
treatment durations and addition of RBV. Depending on the outcome of drug resistance
testing, retreatment strategies contain drugs belonging to the same DAA class as the failing
treatment or they need to be shifted towards other DAA classes (*)
Failed treatment Genotype New treatment Treatment period
pegIFN-α+RBV+TVR/BOC 1 SOF+LDV (+ RBV) 12w – 12/24w (c)
SOF+DCV (+ RBV) 12w – 24w (c)
SOF (+ RBV) (+ pegIFN-α+RBV) 1 SOF+LDV+RBV 12w – 24w (c)
OBV+PTV/r+RBV+DSV 12w – 24w (c)
SOF+SMV+RBV 12w – 24w (c)
SOF+DCV+RBV 12w – 24w (c)
2+3 SOF+DCV (+ RBV) 24w
SOF+pegIFN-α+RBV 12w – 24w (c)
4 SOF+LDV (+ RBV) 12w – 24w (c)
OBV+PTV/r+RBV 12w – 24w (c)
SOF+SMV+RBV 12w – 24w (c)
SOF+DCV+RBV 12w – 24w (c)
5+6 SOF+LDV (+ RBV) 12w – 24w (c)
SOF+DCV+RBV 12w – 24w (c)
pegIFN-α+RBV+SMV 1+4 SOF+LDV (+ RBV) 12w – 12/24w (c)
SOF+DCV (+ RBV) 12w – 24w (c)
pegIFN-α+RBV+DCV 1+4 SOF+SMV+RBV 12w – 24w (c)
2+3 SOF+DCV+RBV 12w – 24w (c)
5+6 SOF+LDV+RBV 12w – 24w (c)
SOF+DCV+RBV 12w – 24w (c)
SOF+SMV 1+4 SOF+LDV+RBV 12w – 24w (c)
SOF+DCV (+ RBV) 12w – 24w (c)
SOF+DCV 1 SOF+DCV+RBV* 24w (+ RBV)
SOF+SMV+RBV* 24w (+ RBV)
SOF+LDV+RBV* 24w (+ RBV)
SOF+LDV 1 SOF+LDV+RBV* 24w (+ RBV)
SOF+SMV+RBV* 24w (+ RBV)
SOF+DCV+RBV* 24w (+ RBV)
PTV/r+OBV+DSV 1 SOF+LDV+RBV* 24w (+ RBV)
SOF+DCV+RBV* 24w (+ RBV)
SOF+SMV+RBV* 24w (+ RBV)
19HCV genotyping for treatment and drug resistance
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epidemiological investigations. Together these
challenges force the continued search for new
pan-genotypic DAAs.
CONCLUSIONS
A correct determination of the HCV genotype in-
fecting a patient remains important to guide the se-
lection of the most appropriate antiviral regimen.
This is because treatment response rates, and the
prevalence and development of drug resistance var-
iants, differ for each DAA regimen, even for the
ones with broader genotypic antiviral activity. Base-
line HCV sequencing can provide important viro-
logical information for a correct genotype/subtype
assignment and for the detection of genetic variants
that can potentially affect therapy response. Even
with the pan-genotypic regimen SOF+VEL, and
other combinations in phase II clinical trials forth-
coming, HCV sequencing can still assist in the selec-
tion of the most appropriate second line regimen, in
patients who need to be retreated after DAA failure.
In the future, even when drug resistance will be-
come a minor issue, HCV viral eradication will still
be hampered because of low diagnosis rates, high
associated costs and high re-infection rates in cer-
tain risk populations.
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SUPPORTING INFORMATION
Additional supporting information may be found in the online version of this article at the publisher’s
web site:
Table 1. References for each country visualized on the world map with the predominant HCV genotypes
(Figure 1). For a large proportion of countries, data was based on two main publications [6–7],
complemented with studies conducted on national or regional levels. Literature was not systematically
reviewed, so not all studies conducted regarding the prevalence of the HCV genotypes, are reported here.
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 Click on the Add stamp icon in the Annotations 
section. 
 Select the stamp you want to use. (The Approved 
stamp is usually available directly in the menu that 
appears). 
 Click on the proof where you’d like the stamp to 
appear. (Where a proof is to be approved as it is, 
this would normally be on the first page). 
7. Drawing Markups Tools – for drawing shapes, lines and freeform 
annotations on proofs and commenting on these marks. 
Allows shapes, lines and freeform annotations to be drawn on proofs and for 
comment to be made on these marks.. 
How to use it 
 Click on one of the shapes in the Drawing 
Markups section. 
 Click on the proof at the relevant point and 
draw the selected shape with the cursor. 
 To add a comment to the drawn shape, 
move the cursor over the shape until an 
arrowhead appears. 
 Double click on the shape and type any 
text in the red box that appears. 
